These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23996116)

  • 21. Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy.
    Sai E; Shimada K; Yokoyama T; Hiki M; Sato S; Hamasaki N; Maruyama M; Morimoto R; Miyazaki T; Fujimoto S; Tamura Y; Aoki S; Watada H; Kawamori R; Daida H
    Heart Vessels; 2017 Feb; 32(2):166-174. PubMed ID: 27142065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of tissue tracking assessment by cardiovascular magnetic resonance for cardiac amyloidosis and hypertrophic cardiomyopathy.
    Jung HN; Kim SM; Lee JH; Kim Y; Lee SC; Jeon ES; Yong HS; Choe YH
    Acta Radiol; 2020 Jul; 61(7):885-893. PubMed ID: 31684748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy.
    Chaowu Y; Shihua Z; Jian L; Li L; Wei F
    Circ Heart Fail; 2013 Sep; 6(5):1013-20. PubMed ID: 23873474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance.
    Rodrigues JC; Amadu AM; Dastidar AG; Hassan N; Lyen SM; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Heart J Cardiovasc Imaging; 2016 Dec; 17(12):1405-1413. PubMed ID: 26705488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.
    Machii M; Satoh H; Shiraki K; Saotome M; Urushida T; Katoh H; Takehara Y; Sakahara H; Ohtani H; Wakabayashi Y; Ukigai H; Tawarahara K; Hayashi H
    Magn Reson Imaging; 2014 Feb; 32(2):118-24. PubMed ID: 24315973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Combination of Feature Tracking and Late Gadolinium Enhancement for Identification Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease.
    Liu S; Li Y; Zhao Y; Wang X; Wu Z; Gu X; Xu B; Li Y; Tian J; Cui J; Wang G; Yu B
    Front Cardiovasc Med; 2022; 9():865615. PubMed ID: 35647085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ongoing assertion of two-dimensional measurements on differentiation type of left ventricular hypertrophy: Focus on inferior vena cava.
    Guler GB; Guler A; Tanboga IH; Turkmen I; Atmaca S; Sahin H; Tekin M; Karakurt ST; Erin F; Inan D; Cinli TA; Akkas BE; Cansever AT; Erturk M
    Echocardiography; 2024 Jul; 41(7):e15880. PubMed ID: 38979714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
    Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.
    Tezuka D; Kosuge H; Terashima M; Koyama N; Kishida T; Tada Y; Suzuki JI; Sasano T; Ashikaga T; Hirao K; Isobe M
    Heart Vessels; 2018 May; 33(5):513-520. PubMed ID: 29168014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrimination models with radiomics features derived from cardiovascular magnetic resonance images for distinguishing hypertensive heart disease from hypertrophic cardiomyopathy.
    Zhang H; Tian J; Zhang C; Wang H; Hui K; Wang T; Chai S; Schoenhagen P; Zhao L; Ma X
    Cardiovasc Diagn Ther; 2024 Feb; 14(1):129-142. PubMed ID: 38434569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left Atrial Performance in the Course of Hypertrophic Cardiomyopathy: Relation to Left Ventricular Hypertrophy and Fibrosis.
    Kowallick JT; Silva Vieira M; Kutty S; Lotz J; Hasenfu G; Chiribiri A; Schuster A
    Invest Radiol; 2017 Mar; 52(3):177-185. PubMed ID: 27741021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography.
    Baccouche H; Maunz M; Beck T; Gaa E; Banzhaf M; Knayer U; Fogarassy P; Beyer M
    Echocardiography; 2012 Jul; 29(6):668-77. PubMed ID: 22486396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation.
    Sipola P; Magga J; Husso M; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Eur Radiol; 2011 Jul; 21(7):1383-9. PubMed ID: 21274714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How are ECG parameters related to cardiac magnetic resonance images? Electrocardiographic predictors of left ventricular hypertrophy and myocardial fibrosis in hypertrophic cardiomyopathy.
    Dohy Z; Vereckei A; Horvath V; Czimbalmos C; Szabo L; Toth A; Suhai FI; Csecs I; Becker D; Merkely B; Vago H
    Ann Noninvasive Electrocardiol; 2020 Sep; 25(5):e12763. PubMed ID: 32329134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.
    Nucifora G; Muser D; Gianfagna P; Morocutti G; Proclemer A
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1603-10. PubMed ID: 26210792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease-specific differences of left ventricular rotational mechanics between cardiac amyloidosis and hypertrophic cardiomyopathy.
    Nucifora G; Muser D; Morocutti G; Piccoli G; Zanuttini D; Gianfagna P; Proclemer A
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H680-8. PubMed ID: 24993044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential diagnosis of common etiologies of left ventricular hypertrophy using a hybrid CNN-LSTM model.
    Hwang IC; Choi D; Choi YJ; Ju L; Kim M; Hong JE; Lee HJ; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ; Cho GY
    Sci Rep; 2022 Dec; 12(1):20998. PubMed ID: 36470931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy.
    Nagakura T; Takeuchi M; Yoshitani H; Nakai H; Nishikage T; Kokumai M; Otani S; Yoshiyama M; Yoshikawa J
    Echocardiography; 2007 Aug; 24(7):677-84. PubMed ID: 17651095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.